ERBB2 and breast carcinoma: We hypothesized that if adding an immune checkpoint inhibitor to anti-ERBB2 treatment enhances the treatment efficacy in patients with ERBB2-positive breast cancer, it could replace carboplatin in the TCHP regimen to improve safety profiles without compromising efficacy by mitigating severe toxic effects from dual cytotoxic chemotherapy.